Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.

This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...

Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza ...

Bengaluru: Biocon Limited, an innovation-led global biopharmaceutical company, has announced the launch of its GLP-1 peptide, ...

Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (U.K.). The drug-device combination will be marketed in the U.K. under the brand names ...

Biocon launches Liraglutide, a GLP-1 peptide, in the UK for diabetes and obesity management. This marks the first generic ...

Liraglutide in United Kingdom: Our Bureau, Bengaluru Friday, February 28, 2025, 15:30 Hrs [IST] Biocon Limited, an innovation-led global ...

Biocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide ...

Shares of Biocon Ltd took a hit on Friday, February 28, 2025, slipping to a day’s low of Rs 300.10, marking a 3.92 per cent ...

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...

Hims & Hers (HIMS) stock tumbled 20% post-market after the company released its Q4 earnings report and 2025 guidance amid a ...